DC_AC50
| 中文名稱 | DC_AC50 |
|---|---|
| 中文同義詞 | 化合物DC_AC50;3-氨基-N-(2-溴-4,6-二氟苯基)-6,7-二氫-5H-環(huán)戊[B]噻吩并[3,2-E]吡啶-2-羧酰胺;3-氨基-N-(2-溴-4,6-二氟苯基)-6,7-二氫-5H-環(huán)戊二烯并[B]噻吩并[3,2-E]吡啶-2-甲酰胺;化合物DC_AC50,10 MM DMSO 溶液 |
| 英文名稱 | 3-amino-N-(2-bromo-4,6-difluorophenyl)-6,7-dihydro-5H-cyclopenta[b]thieno[3,2-e]pyridine-2-carboxamide |
| 英文同義詞 | 3-amino-N-(2-bromo-4,6-difluorophenyl)-6,7-dihydro-5H-cyclopenta[b]thieno[3,2-e]pyridine-2-carboxamide;DC_AC50 (DC-AC50;DC_AC50;5H-Cyclopenta[b]thieno[3,2-e]pyridine-2-carboxamide, 3-amino-N-(2-bromo-4,6-difluorophenyl)-6,7-dihydro-;DC_AC50 >=98% (HPLC);DC_AC-50,resistance,DC_AC50,osteosarcoma,CCS,copper,chaperones,Atox1,inhibit,Apoptosis,Chemotherapy,Inhibitor;DC_AC50, 10 mM in DMSO |
| CAS號 | 497061-48-0 |
| 分子式 | C17H12BrF2N3OS |
| 分子量 | 424.26 |
| EINECS號 | |
| 相關(guān)類別 | |
| Mol文件 | 497061-48-0.mol |
| 結(jié)構(gòu)式 |  |
DC_AC50 性質(zhì)
| 沸點(diǎn) | 485.1±45.0 °C(Predicted) |
|---|---|
| 密度 | 1.759±0.06 g/cm3(Predicted) |
| 儲存條件 | 2-8°C |
| 溶解度 | 溶于二甲基亞砜 |
| 酸度系數(shù)(pKa) | 8.80±0.70(Predicted) |
| 形態(tài) | 粉末 |
| 顏色 | 白色至淺棕色 |
DC_AC50 exhibits IC
50
values of 9.88 μM, 12.57 μM, 5.96 μM and 6.68 μM in Canine Abrams, Canine D1, human HOS and human MG63) cells, respectively.
DC_AC50 (0-10 μM)-treated cells are significantly less mitotically active, as demonstrated by decreased expression of phospho-histone H3 and cell cycle analysis.
DC_AC50 (10 μM) potentiates carboplatin-induced apoptosis in OSA cells and decreasesclonogenic survival.
DC_AC50 induces cell cycle arrest at both the 3 and 10 μM doses and DC_AC50 induces increase S phase cells dose-independently.
DC_AC50 (3 μM) inhibits the migration and of canine and human OSA cells.
DC_AC50 (2.5-10 μM) is highly efficient at inhibiting cancer cell proliferation (human lung cancer H1299 cells, leukaemia cancer K562 cells, breast cancer MDA-MB-231 cells and head and neck cancer 212LN cells) in a dose-dependent manner. DC_AC50 fails to exhibit any notable inhibition of the cell proliferation of human normal epithelial lung BEAS-2B cells or breast MCF-10A cells as control cells.
Cell Viability Assay
| Cell Line: | Canine OSA (Abrams, D1 and human OSA (HOS, MG63) cells. |
| Concentration: | 0-10 μM. |
| Incubation Time: | 72 h. |
| Result: | Dose-dependently decreased viability of OSA cells. |
Apoptosis Analysis
| Cell Line: | Abrams and HOS cells. |
| Concentration: | 1, 3 and 10 μM (10 μM Carboplatin). |
| Incubation Time: | 24 h. |
| Result: | Potentiated carboplatin-induced apoptosis. |
安全信息
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
|---|---|---|---|---|---|
| 2025/05/22 | HY-107636 | DC_AC50 | 497061-48-0 | 1 mg | 386元 |
| 2025/05/22 | HY-107636 | DC_AC50 | 497061-48-0 | 10 mM * 1 mLin DMSO | 793元 |